VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B‐cell lymphoma.

MLA

Kaddu, Mulindwa, Dominic, et al. “VEGFR2 and VEGFA Polymorphisms Are Not Associated with an Inferior Prognosis in Caucasian Patients with Aggressive B‐cell Lymphoma.” European Journal of Haematology, vol. 106, no. 1, Jan. 2021, pp. 100–04. EBSCOhost, https://doi.org/10.1111/ejh.13526.

APA

Kaddu, M. D., Rosolowski, M., Ziepert, M., Regitz, E., Assmann, G., Bewarder, M., Held, G., Pfreundschuh, M., & Bittenbring, J. T. (2021). VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B‐cell lymphoma. European Journal of Haematology, 106(1), 100–104. https://doi.org/10.1111/ejh.13526

Chicago

Kaddu, Mulindwa, Dominic, Maciej Rosolowski, Marita Ziepert, Evi Regitz, Gunter Assmann, Moritz Bewarder, Gerhard Held, Michael Pfreundschuh, and Jörg Thomas Bittenbring. 2021. “VEGFR2 and VEGFA Polymorphisms Are Not Associated with an Inferior Prognosis in Caucasian Patients with Aggressive B‐cell Lymphoma.” European Journal of Haematology 106 (1): 100–104. doi:10.1111/ejh.13526.